CataractPHY2107NCT05255029
Clinical Investigation of a Monofocal Toric Intra Ocular Lens (IOL) in Cataractous Eyes
A study testing POD T 49P implantation experimental in people with Cataract and Lens Opacities, run by Beaver-Visitec International, Inc. at 4 sites in Japan.
Trial summary
This is a Multi-center, single-arm and non-masked study whereby patients undergoing routine cataract surgery be implanted with a hydrophobic acrylic monofocal toric intraocular lens PODEYE TORIC (model POD T 49P). Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Cataract, Lens Opacities, Astigmatism
- What is being tested?
- POD T 49P implantation experimental
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 4 sitesJapan
- Study dates
- 24 Dec 2021to 28 Feb 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
The patient who meets all criteria specified in the following 1) through 8)
- Adults, 20 years of age or older at the time of informed consent, of either gender, diagnosed with cataract;
- Able to comprehend and sign a statement of informed consent;
- Willing and able to complete all required postoperative visits;
- Calculated lens power within the available range;
- Subject with corneal astigmatism or subjects who is judged by the investigator or investigator to correct of astigmatism as a result of considering the predicted surgical induced astigmatism.
- Planned cataract removal by phacoemulsification;
- Target postoperative refraction is emmetropia and potential postoperative Collected Distance Visual Acuity (CDVA) of 0.5 decimal or better in both eyes;
- Clear intraocular media other than cataract in both eyes;
[Justification for the inclusion criteria]
1 and 6: Cataract extraction is the indication of the clinical study. 2 and 3: One of GCP requirements 4 and 5: Essential condition for implant of the investigational lens. 7 and 8: Conditions to minimize the potential non-IOL factors which may affect the visual acuity data
(3) Exclusion Criteria [Exclusion Criteria Prior to Surgery] The patient who meets any criteria specified in the following 1) through 20).
- Subjects with diseases that affect postoperative visual acuity in the cornea (keratitis, corneal degeneration, corneal dilatation, corneal edema);
- Previous corneal transplant;
- Previous refractive surgery;
- Irregular corneal aberration
- Subjects with diseases that affect postoperative visual acuity in the retina (retinal degeneration, diabetic retinopathy, retinal detachment);
- Poor mydriasis;
- Glaucoma or ocular hypertension;
- Optic nerve atrophy;
- Extremely shallow anterior chamber;
- Aniridia;
- Iris neovascularization;
- Microphthalmos;
- Amblyopia;
- Rubella, atopic or traumatic cataract;
- Recurrent severe anterior or posterior segment inflammation of unknown etiology;
- Subjects who may be expected to require ocular surgery during this study;
- The axial length cannot be measured with an optical biometry;
- Pregnancy, lactating or possible pregnant;
- Participation in any clinical study (drug or device) within 3 months prior to participating this study, planned participation another clinical study during this study, or currently participating in another study.
- Disqualified by the investigator or the sub-investigator because of physical or ophthalmic diseases
[Exclusion Criteria During Surgery] The patient who meets any criteria specified in the following 1) through 8).
- Mechanical or surgical manipulation required to enlarge the pupil;
- Excessive iris mobility;
- Uncontrollable intraocular pressure;
- Continuous Curvilinear Capsulorrhexis (CCC) with incomplete circle or tear;
- Zonular or capsular rupture or tear;
- Significant anterior chamber hyphema;
- Significant vitreous loss;
- IOL could not be fixed in the lens capsule;
In the event of zonular damage, capsulorhexis tear, or decentered capsulorhexis during surgery, the surgeon should decide whether the stability of the Intra Ocular Lens (IOL) would be compromised by the complication. If the IOL stability would be compromised, the investigational IOL should not be implanted, the subject should be discontinued from the study, and the surgeon should make arrangements to implant an alternative non-investigational IOL.
[Justifications for the exclusion criteria] {Exclusion Criteria Prior to Surgery} 1, 2, 3, 4, 5, 7, 8, 14, 15, 16 and 20: Factors potentially affecting effectiveness evaluability and criteria to secure safety of study subjects 6, 13 and17: Factors potentially affecting effectiveness evaluability 9, 10, 11, 12, 18 and 19: Criteria to secure safety of study subjects
{Exclusion Criteria During Surgery}
1, 2, 4, 5 and 8: Factors potentially affecting effectiveness evaluability 3, 6 and 7: Criteria to secure safety of study subjects
Trial locations and contacts
4 sites in 1 country.
Japan4 sites
Roppongi Shiba Eye Clinic
Minato-Ku, Tokyo
Miyata Eye Hospital
Miyazaki
Chukyo Eye Clinic
Nagoya, Aichi-ken
Fujita Eye Clinic
Tokushima
About this study
Official title: Clinical Investigation of the Monofocal Toric IOL POD T 49P in Cataractous Eyes
This is a Multi-center, single-arm and non-masked study whereby patients undergoing routine cataract surgery be implanted with a hydrophobic acrylic monofocal toric intraocular lens PODEYE TORIC (model POD T 49P).
Read the detailed description
This is a Multi-center, single-arm and non-masked study whereby patients undergoing routine cataract surgery will be implanted with a hydrophobic acrylic monofocal toric intraocular lens PODEYE TORIC. The device under investigation is a hydrophobic acrylic monofocal toric intraocular lens (IOL) manufactured by the sponsor of this study (BVI Medical). The refractive power of the lens has a spherical and a cylindrical component. The IOLs will be implanted in the course of routine cataract surgery and will benefit to patients suffering from cataract development and showing pre-existing corneal astigmatism.
In total approx. 28 patients, 56 eyes will be recruited for this clinical study and undergo implantation of PODEYE TORIC intraocular lens.
Subjects participating in the trial will attend a total of maximum 6 study visits over a period of 120-180 days (preoperative, operative, 1-2 days, 7-14 days, 30-60 days, 120-180 days, postoperative visits). Subjects would have the option for unscheduled visits if required medically.
- Conditions
- Cataract, Lens Opacities, Astigmatism
- Being tested
- POD T 49P implantation experimental
- Keywords
- Intraocular Lens, Monofocal, Toric Lens
- Medical subject headings
- Cataract, Astigmatism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
POD T 49P implantation experimentalDevice
The investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye.
| Study group | Role | What they receive |
|---|---|---|
| PODEYE Toric Intra Ocular Lens Implantation experimental | Experimental | Implantation of PODEYE toric intraocular lenses. Receives: Device: POD T 49P implantation experimental |
What is being measured
The primary outcome is the main question the study is designed to answer.
Uncorrected visual acuity at Visit 4
Uncorrected visual acuity at 5 m will be measured. Convert decimal visual acuity to logMAR value using the following formula.
logMAR value = log10 (1/decimal visual acuity)
Measured: Postoperative Day 120-180
Amount of astigmatism at Visit 4
Manifest cylindrical refraction for Best Collected Distance Visual Acuity will be measured at Visit 4.
Measured: Postoperative Day 120-180
Secondary outcomes (3)
Best Corrected Distance Visual Acuity
Best Corrected Distance Visual Acuity at 5 m will be measured. The objective is to compare CDVA above defined thresholds of the investigational product.
Measured: Pre-Op, 1 week postoperative, 1 month postoperative, 6 months postoperative.
Manifest cylindrical refraction
Manifest cylindrical refraction for Best Collected Distance Visual Acuity will be measured.
Measured: Pre-Op, 1 month postoperative, 6 months postoperative
IOL rotation
After mydriasis, a photograph of the anterior segment of the test lens is taken using an anterior segment analyzer, and the angle of the toric mark with respect to the horizon is measured as the axial angle. Calculate the number of the eye and the percentage of less than 5 degrees, more than 5 degrees to less than 10 degrees, more than 10 degrees to less than 20 degrees.
Measured: Pre-Op, 1 month postoperative, 6 months postoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2022
- Study start24 Dec 2021
- Primary completion28 Feb 2023
- Study completion28 Feb 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CataractStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- 1\) Summary of investigational lens Model: POD T 49P General name: PODEYE Toric Construction Single-piece construction lens consisting of the optic and the haptic made of the same material, optic diameter: 6.0 mm, overall length: 11.4 mm (Fig.1). Cylinder power is added on the posterior optics.
- Masking
- None (open label)
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beaver-Visitec International, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- MIYATA Kazunori, MD, Principal investigator, Miyata Eye Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05255029
- Sponsor's protocol ID
- PHY2107
- Acronym
- PHY2107
- Status last verified
- Jul 2023
- First submitted
- 26 Nov 2021
- Last updated
- 19 Jul 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Investigation of the Monofocal Toric IOL POD T 49P in Cataractous Eyes
- ClinicalTrials.gov ID
- NCT05255029
- Acronym / sponsor ID
- PHY2107 / PHY2107
- Conditions
- Cataract, Lens Opacities, Astigmatism
- Keywords
- Intraocular Lens, Monofocal, Toric Lens
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Beaver-Visitec International, Inc.Industry (pharma, biotech, devices)
- Study start
- 24 Dec 2021 (actual)
- Primary completion
- 28 Feb 2023 (actual)
- Study completion
- 28 Feb 2023 (actual)
- First posted
- 24 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Multi-center, single-arm and non-masked study whereby patients undergoing routine cataract surgery be implanted with a hydrophobic acrylic monofocal toric intraocular lens PODEYE TORIC (model POD T 49P).
Detailed description
This is a Multi-center, single-arm and non-masked study whereby patients undergoing routine cataract surgery will be implanted with a hydrophobic acrylic monofocal toric intraocular lens PODEYE TORIC. The device under investigation is a hydrophobic acrylic monofocal toric intraocular lens (IOL) manufactured by the sponsor of this study (BVI Medical). The refractive power of the lens has a spherical and a cylindrical component. The IOLs will be implanted in the course of routine cataract surgery and will benefit to patients suffering from cataract development and showing pre-existing corneal astigmatism.
In total approx. 28 patients, 56 eyes will be recruited for this clinical study and undergo implantation of PODEYE TORIC intraocular lens.
Subjects participating in the trial will attend a total of maximum 6 study visits over a period of 120-180 days (preoperative, operative, 1-2 days, 7-14 days, 30-60 days, 120-180 days, postoperative visits). Subjects would have the option for unscheduled visits if required medically.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- 1) Summary of investigational lens Model: POD T 49P General name: PODEYE Toric Construction Single-piece construction lens consisting of the optic and the haptic made of the same material, optic diameter: 6.0 mm, overall length: 11.4 mm (Fig.1). Cylinder power is added on the posterior optics.
| Arm | Type | Receives |
|---|---|---|
| PODEYE Toric Intra Ocular Lens Implantation experimental | Experimental | Device: POD T 49P implantation experimentalImplantation of PODEYE toric intraocular lenses. |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| POD T 49P implantation experimentalThe investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye. | Device | PODEYE Toric Intra Ocular Lens Implantation experimental |
Primary outcome
Uncorrected visual acuity at Visit 4
Time frame: Postoperative Day 120-180
Uncorrected visual acuity at 5 m will be measured. Convert decimal visual acuity to logMAR value using the following formula. logMAR value = log10 (1/decimal visual acuity)
Amount of astigmatism at Visit 4
Time frame: Postoperative Day 120-180
Manifest cylindrical refraction for Best Collected Distance Visual Acuity will be measured at Visit 4.
3 secondary outcomes
Best Corrected Distance Visual Acuity
Time frame: Pre-Op, 1 week postoperative, 1 month postoperative, 6 months postoperative.
Manifest cylindrical refraction
Time frame: Pre-Op, 1 month postoperative, 6 months postoperative
IOL rotation
Time frame: Pre-Op, 1 month postoperative, 6 months postoperative
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jul 2023.
- Individual participant dataSharing planned: No
Related trials for Cataract
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Active, not recruitingObservational study
Age-Related Eye Disease Study (AREDS) Follow-Up
Age-Related Macular Degeneration, Cataract
Not yet recruiting
Effects of Oxygen Cage Support During Cataract Surgery
Cataract
Not yet recruiting
Safety and Clinical Performance of the LENTIS® MAX LS-313 MF80 Compared With the Monofocal L-313 in Cataract Patients With Late Age-Related Macular Degeneration: A Multicenter Comparative Clinical Investigation.
Cataract, AMD - Age-Related Macular Degeneration
RecruitingObservational study
Capella Scientia Development Study
Cataract
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MIYATA Kazunori, MD principal investigator
Miyata Eye Hospital
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing POD T 49P implantation experimental in people with Cataract and Lens Opacities, run by Beaver-Visitec International, Inc. at 4 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Uncorrected visual acuity at Visit 4 (time frame: Postoperative Day 120-180). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2023; AzTrials last refreshed its copy on 8 Nov 2026.